Abstract:Abstract Background: Prostate Cancer (PCa) is the most common non-skin cancer among American man. Currently, major challenges in the clinical management of PCa include 1) a lack of biomarkers that can reliably distinguish aggressive from indolent PCa and 2) a shortage of therapeutic strategies that can prevent or suppress the progression of PCa into aggressive PCa. Methods: Label-free quantitative proteomics was performed on three widely used PCa cell lines with different levels of aggressiveness (i.e., LNCaP, DU145 and PC3). Upstream regulator analysis and network modeling were conducted to identify candidate key promoters of PCa aggressiveness. The levels of gene amplification, mRNA expression, and protein expression of a key candidate promoter, receptor-interacting protein kinase 2 (RIPK2), were compared by analyzing publicly accessible PCa genomic and transcriptomic datasets and by immunohistochemistry (IHC) staining of PCa tissue microarrays (TMA). Cell proliferation and invasion assays were performed to compare PC3 cells with or without CRISPR/Cas9 knock-out of RIPK2. Quantitative proteomics and bioinformatics analysis were conducted to identify the underlying mechanisms, followed by validation via western blotting, quantitative real-time PCR (qRT-PCR) and in vitro functional assays. Results: Quantitative proteomics analysis of the three PCa cell lines identified over 6,500 proteins, among which 341 are significantly (adjusted p-value < 0.01) differentially expressed. Bioinformatic analysis and network modeling revealed RIPK2 as a novel candidate key promoter of aggressive PCa. Consistently, the levels of RIPK2 DNA amplification, mRNA expression, and protein expression are significantly higher in more aggressive PCa than in less aggressive PCa. Moreover, cell functional assays showed a significant inhibition of cell proliferation and invasion after the CRISPR/Cas9 depletion of RIPK2 in PC3 cells. Mechanistically, quantitative proteomics identified MAX (Myc-associated factor X) as one of the most prominent candidate downstream effectors of RIPK2. Consistently, upstream regulator analysis suggested that Myc activity was significantly downregulated in RIPK2 deleted PC3 cells, compared with control cells. These findings were further validated by RT-PCR, western blotting, and MYC luciferase reporter assay. In addition, pathway enrichment analysis identified the EIF2 signaling pathway, a key pathway regulated by MAX:MYC, as the most significantly downregulated pathway after RIPK2 knock-out. Conclusion: Taken together, our data elucidate that RIPK2's amplification and overexpression in PCa cells may activate the MAX:MYC-EIF2 signaling axis and thus in turn promote PCa cell proliferation and invasion. The aberrant activation of the RIPK2-MAX:MYC-EIF2 pathway may serve as a valuable biomarker and novel drug target of PCa progression. Citation Format: Yiwu Yan, Bo Zhou, Xiaopu Yuan, Michael E. Doche, Zhaoxuan Ma, Colm Morrissey, Arkadiusz Gertych, Sungyong You, Beatrice Knudsen, Michael R. Freeman, Wei Yang. Receptor-interacting protein kinase 2 promotes prostate cancer progression by activating the MAX:MYC pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2694.

Mp99-04 truncated-crmp4 by calpain-2 suppresses crmp4 to promote metastasis of prostate cancer via promoter methylation through e2f1/nf-?b/dnmt1 signaling

Calpain-2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF-κB/DNMT1 signaling pathway.

CRMP4 Suppresses Cervical Cancer Cell Proliferation and EMT Through the Wnt/β-catenin Pathway

CRABP2 Promotes Cell Migration and Invasion by Activating PI3K/AKT and MAPK Signalling Pathways Via Upregulating LAMB3 in Prostate Cancer

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer

Upregulation of CRMP4, a New Prostate Cancer Metastasis Suppressor Gene, Inhibits Tumor Growth in a Nude Mouse Intratibial Injection Model.

MP99-07 AP4 PROMOTES PROLIFERATION AND METASTASIS OF CASTRATION-RESISTANT PROSTATE CANCER THROUGH BINDING AND UP-REGULATION OF L-PLASTIN

A novel methylated cation channel TRPM4 inhibited colorectal cancer metastasis through Ca<SUP>2+</SUP>/Calpain-mediated proteolysis of FAK and suppression of PI3K/Akt/mTOR signaling pathway

Lung Cancer Metastasis-Related Protein 1 Promotes the Transferring from Advanced Metastatic Prostate Cancer to Castration-Resistant Prostate Cancer by Activating the Glucocorticoid Receptor Α Signal Pathway.

Prospective Study Of Crmp4 Promoter Methylation In Prostate Biopsies As A Predictor For Lymph Node Metastases

MAPK4 Promotes Prostate Cancer by Concerted Activation of Androgen Receptor and AKT.

Abstract 2694: Receptor-interacting Protein Kinase 2 Promotes Prostate Cancer Progression by Activating the MAX:MYC Pathway

Mitogen-activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis.

Targeting TR4 Nuclear Receptor Suppresses Prostate Cancer Invasion Via Reduction of Infiltrating Macrophages with Alteration of the TIMP-1/MMP2/MMP9 Signals

Manipulation of Prostate Cancer Metastasis by Locus-Specific Modification of the CRMP4 Promoter Region Using Chimeric TALE DNA Methyltransferase and Demethylase

Activation of MCP-1/CCR2 axis promotes prostate cancer growth in bone

Abstract 6284: Multimoics reveal aberrant pathways and regulation of castration resistant and metastatic prostate cancer

Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway

MP62-19 AKR1C3 OVEREXPRESSION IN PROSTATE CANCER PROMOTES EPITHELIAL-MESENCHYMAL TRANSITION AND METASTASIS VIA ACTIVATION OF MAPK/ERK SIGNALING AND UPREGULATION OF ZEB1